Skip to main content
    A

    AngioDynamics Inc (ANGO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $11.87
    -0.11 (-0.96%)

    Market Cap: $499.19M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AngioDynamics Inc (ANGO) Financials: Revenue, Profit and Cash Flow

    Updated Oct 8, 2026. Financial statements from company filings, amounts in US dollars.

    AngioDynamics reported revenue of $320.17M for the fiscal year ended May 31, 2026, up 9.5% from the year before. That year, net income was -$36.74M with a net margin of -11.5%, operating cash flow was $3.09M and free cash flow was $508.00K. The quarter ended Aug 31, 2026 had revenue of $80.92M and net income of -$7.10M.

    Revenue and Margins

    The operating margin was -12.5% in the fiscal year ended May 2026. Over the 9 years to May 2026, revenue grew from $269.79M, a compound annual rate of 1.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    May 2026$320.17M+9.5%54.6%-12.5%-11.5%
    May 2025$292.50M-3.8%53.9%-13.7%-11.6%
    May 2024$303.91M-10.3%50.9%-63.3%-60.7%
    May 2023$338.75M+7.1%51.4%-15.1%-15.5%
    May 2022$316.22M+8.7%52.4%-9.0%-8.4%
    May 2021$291.01M+10.2%53.9%-12.1%-10.8%
    May 2020$264.16M-2.4%56.9%-63.3%-63.1%
    May 2019$270.63M+3.4%57.6%-3.5%22.7%
    May 2018$261.65M-3.0%55.0%-5.4%6.2%
    May 2017$269.79MN/A53.4%-4.1%1.9%
    Annual, fiscal years ended May 2017 to May 2026

    Income Statement

    In the fiscal year ended May 2026, the net loss widened from the year before. In the quarter ended Aug 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMay 2026May 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017
    Revenue$320.17M$292.50M$303.91M$338.75M$316.22M$291.01M$264.16M$270.63M$261.65M$269.79M
    Cost of revenue$145.28M$134.79M$149.22M$164.51M$150.49M$134.22M$113.89M$114.63M$117.80M$125.84M
    Gross profit$174.89M$157.71M$154.70M$174.25M$165.73M$156.79M$150.27M$156.00M$143.86M$143.95M
    Research and development$29.45M$26.22M$31.51M$29.88M$30.74M$36.39M$29.68M$28.26M$24.34M$24.15M
    Operating income-$39.93M-$39.95M-$192.44M-$51.18M-$28.47M-$35.28M-$167.10M-$9.40M-$14.17M-$11.18M
    Net income-$36.74M-$33.99M-$184.35M-$52.44M-$26.55M-$31.55M-$166.79M$61.34M$16.34M$5.01M
    EBITDA-$13.05M-$9.21M-$165.54M-$20.86M$88.00K-$9.28M-$143.42M$16.28M$8.96M$13.36M
    Fiscal years ended May 2017 to May 2026

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Revenue$80.92M$86.61M$78.42M$79.43M$75.71M$80.16M$72.00M$72.84M$67.49M$70.98M$75.18M$79.07M
    Gross profit$48.04M$46.77M$41.48M$44.78M$41.86M$42.22M$38.86M$39.91M$36.72M$38.52M$35.86M$40.26M
    Operating income-$7.30M-$10.20M-$12.95M-$6.13M-$10.66M-$5.79M-$9.97M-$11.09M-$13.10M-$14.45M-$199.90M-$13.12M
    Net income-$7.10M-$11.40M-$8.08M-$6.35M-$10.90M-$6.05M-$4.41M-$10.74M-$12.80M-$13.45M-$187.74M-$29.05M
    Last 12 quarters

    Balance Sheet

    As of May 2026, cash and equivalents of $53.86M were 20.2% of total assets of $267.16M, against total liabilities of $96.34M.

    Annual

    Line itemMay 2026May 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017
    Total assets$267.16M$280.14M$317.67M$532.64M$552.75M$561.44M$594.21M$836.44M$705.47M$707.96M
    Current assets$163.39M$168.32M$193.25M$163.54M$143.34M$140.88M$152.91M$315.29M$168.03M$153.91M
    Cash and equivalents$53.86M$55.89M$76.06M$44.62M$28.82M$48.16M$54.44M$227.64M$74.10M$47.54M
    Total liabilities$96.34M$97.17M$112.08M$154.34M$128.26M$121.98M$139.34M$221.62M$162.88M$192.93M
    Short-term debtN/A$2.24M$4.73M$14.76M$8.78M$0$836.00K$12.13M$7.10M$14.63M
    Long-term debtN/AN/AN/A$49.82M$25.00M$20.00M$40.00M$124.41M$86.62M$91.32M
    Shareholder equity$170.82M$182.97M$205.59M$378.30M$424.49M$439.46M$454.87M$614.82M$542.60M$515.03M
    Fiscal years ended May 2017 to May 2026

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Total assets$241.93M$267.16M$260.68M$269.68M$265.64M$280.14M$285.42M$291.55M$293.63M$317.67M$324.84M$499.62M
    Total liabilities$77.97M$96.34M$87.32M$93.35M$86.79M$97.17M$99.55M$104.78M$97.05M$112.08M$106.14M$98.40M
    Cash and equivalents$33.97M$53.86M$37.81M$41.64M$38.76M$55.89M$44.76M$54.09M$55.01M$76.06M$78.45M$60.90M
    Shareholder equity$163.96M$170.82M$173.36M$176.33M$178.85M$182.97M$185.87M$186.77M$196.58M$205.59M$218.70M$401.23M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended May 2026, free cash flow was 16.4% of operating cash flow.

    Annual

    Line itemMay 2026May 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017
    Operating cash flow$3.09M-$10.13M-$28.16M$78.00K-$7.19M$24.09M-$14.55M$37.44M$41.29M$55.74M
    Capital expenditures$2.58M$4.46M$2.52M$3.81M$4.30M$5.19M$7.24M$3.12M$2.39M$3.00M
    Free cash flow$508.00K-$14.59M-$30.68M-$3.73M-$11.49M$18.91M-$21.79M$34.32M$38.90M$52.74M
    Share repurchases$0$1.67M$0$0N/AN/AN/AN/AN/A$13.56M
    Investing cash flow-$5.95M-$10.18M$123.72M-$9.75M-$19.31M-$13.71M-$63.34M$82.55M-$3.66M-$2.55M
    Financing cash flow$564.00K-$255.00K-$64.25M$25.42M$7.68M-$16.99M-$95.24M$33.93M-$11.55M-$37.98M
    Fiscal years ended May 2017 to May 2026

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Operating cash flow-$15.33M$17.45M-$3.11M$4.66M-$15.91M$18.81M-$13.16M$2.47M-$18.25M$5.00M-$12.53M$5.27M
    Capital expenditures$3.15M$2.10M$1.51M$1.62M$1.55M$3.09M$3.19M$1.96M$2.40M$2.68M$1.85M$1.79M
    Free cash flow-$18.48M$15.35M-$4.62M$3.04M-$17.46M$15.72M-$16.35M$512.00K-$20.66M$2.32M-$14.37M$3.47M
    Last 12 quarters

    Frequently Asked Questions About ANGO

    What is AngioDynamics' annual revenue?

    AngioDynamics reported revenue of $320.17M for the fiscal year ended May 31, 2026.

    How fast is AngioDynamics' revenue growing?

    Revenue was up 9.5% for the fiscal year ended May 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -1.9%.

    Is AngioDynamics profitable?

    No. AngioDynamics reported net income of -$36.74M for the fiscal year ended May 31, 2026, with a net margin of -11.5%.

    How much free cash flow does ANGO generate?

    For the fiscal year ended May 31, 2026, operating cash flow of $3.09M minus capital expenditures of $2.58M produced free cash flow of $508.00K.

    How much debt does AngioDynamics have?

    The balance sheet dated May 31, 2026 reported cash and equivalents of $53.86M.